Pacira BioSciences Notified of Abbreviated New Drug Application Filing
Pacira BioSciences, Inc. (Nasdaq: PCRX), a leader in non-opioid pain therapies, reported receiving a Paragraph IV Certification Notice Letter from Qilu Pharmaceutical (Hainan) Co., Ltd.
Qilu has filed an Abbreviated New Drug Application with the FDA for a product claiming to be a generic equivalent of EXPAREL, alleging that 18 EXPAREL patents are invalid.
Qilu alleges that the claims of 18 EXPAREL patents listed in the FDA's Orange Book are invalid.
- Company: Pacira BioSciences, Inc. (Nasdaq: PCRX)
- Product: EXPAREL
- Filing: Abbreviated New Drug Application (ANDA)
Author summary: Pacira BioSciences notified of generic EXPAREL application filing.
More News
- Mystery of The Ocean's Missing Plastic a Step Closer to Being Solved
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Congress Eyes New Cyber and Communications Powers for the National Guard
- Global PAH data shows rising cases and risk factors in elderly
- Global PAH data shows rising cases and risk factors in elderly
- Importing beef is not the solution | GABEL
- SLO County Touts Improved Public Safety with Opening of New Communications Center | News Channel 3-12
- Battlefield 6's Battle Royale Mode Is Called REDSEC, Is Free-To-Play, And Launches Tomorrow
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- West Indies ease past Bangladesh in first T20I